全文获取类型
收费全文 | 15030篇 |
免费 | 946篇 |
国内免费 | 165篇 |
专业分类
耳鼻咽喉 | 223篇 |
儿科学 | 271篇 |
妇产科学 | 266篇 |
基础医学 | 2347篇 |
口腔科学 | 658篇 |
临床医学 | 1131篇 |
内科学 | 3200篇 |
皮肤病学 | 726篇 |
神经病学 | 1084篇 |
特种医学 | 752篇 |
外科学 | 1858篇 |
综合类 | 56篇 |
现状与发展 | 1篇 |
一般理论 | 3篇 |
预防医学 | 890篇 |
眼科学 | 368篇 |
药学 | 1302篇 |
中国医学 | 190篇 |
肿瘤学 | 815篇 |
出版年
2024年 | 15篇 |
2023年 | 129篇 |
2022年 | 334篇 |
2021年 | 551篇 |
2020年 | 283篇 |
2019年 | 389篇 |
2018年 | 582篇 |
2017年 | 441篇 |
2016年 | 577篇 |
2015年 | 715篇 |
2014年 | 825篇 |
2013年 | 928篇 |
2012年 | 1432篇 |
2011年 | 1382篇 |
2010年 | 713篇 |
2009年 | 597篇 |
2008年 | 902篇 |
2007年 | 800篇 |
2006年 | 709篇 |
2005年 | 724篇 |
2004年 | 545篇 |
2003年 | 481篇 |
2002年 | 417篇 |
2001年 | 259篇 |
2000年 | 283篇 |
1999年 | 203篇 |
1998年 | 80篇 |
1997年 | 42篇 |
1996年 | 46篇 |
1995年 | 27篇 |
1994年 | 45篇 |
1993年 | 25篇 |
1992年 | 57篇 |
1991年 | 65篇 |
1990年 | 67篇 |
1989年 | 74篇 |
1988年 | 49篇 |
1987年 | 45篇 |
1986年 | 34篇 |
1985年 | 38篇 |
1984年 | 21篇 |
1983年 | 14篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 22篇 |
1979年 | 20篇 |
1978年 | 13篇 |
1977年 | 14篇 |
1971年 | 12篇 |
1970年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Aditya Kelkar Caroll Webers Rohit Shetty Jai Kelkar Nikhil Labhsetwar Abhishek Pandit Madhulika Malode Sayali Tidke 《Indian journal of ophthalmology》2020,68(10):2143
Purpose:To evaluate the rate of compliance and the reasons for loss to follow-up in Indian patients with diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) being treated with anti-vascular endothelial growth factor (VEGF) therapy.Methods:This was a retrospective single-center study. Patients with DME, AMD, or RVO were eligible if they initiated anti-VEGF therapy between January 2013 and December 2017. Patients'' data were obtained from hospital electronic records, including the number of injections received, visits, details of follow-up, missed appointments, and reasons for loss to follow-up (>365 days).Results:A total of 648 patients were eligible for the study, of which 334 (51.54%) patients were lost to follow-up. Overall, 343 (64.96%) were males and the overall mean (SD) age was 66.40 (7.44) years. A total of 376 (58.0%) patients had a history of diabetes and 364 (56.2%) patients had a history of hypertension. Further, 127 (38.0), 112 (33.5), and 95 (28.4) had DME, AMD, and RVO, respectively and were lost to follow-up. The most commonly reported reason for loss to follow-up was “non-affordability” (n = 120; 41.1%) followed by “no improvement in vision” (n = 83; 28.4%). “No improvement in vision” (42.2%) and “non-affordability” (37.5%) were higher among patients with DME. No association was found in gender- and treatment-wise distribution of reasons for loss to follow-up.Conclusion:The results showed that around half of the patients with DME, AMD, and RVO were lost to follow-up to intravitreal anti-VEGF therapy, and the most common factors were “non-affordability” and “no improvement in vision.” 相似文献
3.
4.
5.
Clinical usefulness of intraductal ultrasonography for the management of acute biliary pancreatitis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
7.
8.
9.
K.-C. Sung D.-C. Seo S.-J. Lee M.-Y. Lee S.H. Wild C.D. Byrne 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(5):489-495
Background and aims
It is not known whether non alcoholic fatty liver disease (NAFLD) is a risk factor for diabetes in non obese, non centrally-obese subjects. Our aim was to investigate relationships between fatty liver, insulin resistance and a biomarker score for liver fibrosis with incident diabetes at follow up, in subjects who were neither obese nor centrally-obese.Methods and results
As many as 70,303 subjects with a body mass index (BMI) < 25 kg/m2 and without diabetes were followed up for a maximum of 7.9 years. At baseline, fatty liver was identified by liver ultrasound, insulin resistance (IR) by homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0, and central obesity by waist circumference (waist circumference ≥90 cm (men) and ≥85 cm (women). The Fibrosis-4 (FIB-4 score) was used to estimate extent of liver fibrosis. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (aHRs) for incident diabetes. As many as 852 incident cases of diabetes occurred during follow up (median [IQR] 3.71 [2.03] years). Mean ± SD BMI was 22.8 ± 1.8 and 21.7 ± 2.0 kg/m2 in subjects with and without diabetes at follow up. In subjects without central obesity and with fatty liver, aHRs (95% CI) for incident diabetes at follow up were 2.17 (1.56, 3.03) for men, and 2.86 (1.50,5.46) for women. Similar aHRs for incident diabetes occurred with fatty liver, IR and the highest quartile of FIB-4 combined, in men; and there was a non significant trend toward increased risk in women.Conclusions
In normal weight, non-centrally obese subjects NAFLD is an independent risk factor for incident diabetes. 相似文献10.
Xiaoqing Guo Ji-Eun Seo Xilin Li Nan Mei 《Journal of toxicology and environmental health. Part B, Critical reviews》2020,23(1):27-50
ABSTRACTGenotoxic compounds may be detoxified to non-genotoxic metabolites while many pro-carcinogens require metabolic activation to exert their genotoxicity in vivo. Standard genotoxicity assays were developed and utilized for risk assessment for over 40 years. Most of these assays are conducted in metabolically incompetent rodent or human cell lines. Deficient in normal metabolism and relying on exogenous metabolic activation systems, the current in vitro genotoxicity assays often have yielded high false positive rates, which trigger unnecessary and costly in vivo studies. Metabolically active cells such as hepatocytes have been recognized as a promising cell model in predicting genotoxicity of carcinogens in vivo. In recent years, significant advances in tissue culture and biological technologies provided new opportunities for using hepatocytes in genetic toxicology. This review encompasses published studies (both in vitro and in vivo) using hepatocytes for genotoxicity assessment. Findings from both standard and newly developed genotoxicity assays are summarized. Various liver cell models used for genotoxicity assessment are described, including the potential application of advanced liver cell models such as 3D spheroids, organoids, and engineered hepatocytes. An integrated strategy, that includes the use of human-based cells with enhanced biological relevance and throughput, and applying the quantitative analysis of data, may provide an approach for future genotoxicity risk assessment. 相似文献